Professor, Johns Hopkins University
Oncology
Dr. Kenneth J. Pienta, MD
|
|
Give Review
Doctor Kenneth J. Pienta, MD works in the field of Oncology. He graduated from Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical university. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He over the years received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "CMS Meaningful Use Stage 1 Certification" and "Elected Member". Kenneth Pienta is a published MD. He has 101 papers published. The most current publication "Disseminated tumor cells and dormancy in prostate cancer metastasis." Kenneth J. Pienta, MD is registered with Medicare and accepts Medicare payments.
Publications
- Multidisciplinary intervention of early, lethal metastatic prostate Cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.
- Polyclonal breast Cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters.
- Disseminated tumor cells and dormancy in prostate Cancer metastasis.
- Bone marrow macrophages support prostate Cancer growth in bone.
- Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast Cancer cells.
- Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate Cancer: Report from the 2014 Coffey-Holden prostate Cancer Academy m...
- Epithelial-mesenchymal transition in prostate Cancer is associated with quantifiable changes in nuclear structure.
- Genetic ablation of metadherin inhibits autochthonous prostate Cancer progression and metastasis.
- The presence of Androgen Receptor Elements regulates ZEB1 expression in the absence of Androgen Receptor.
- Polarization of Prostate Cancer Associated Macrophages is Induced by Milk-Fat Globule-EGF Factor 8 (MFG-E8) Mediated Efferocytosis.
- Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant pros...
- Dynamic regulation of Rad51 by E2F1 and p53 in prostate Cancer cells upon drug-induced DNA damage under hypoxia.
- Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy.
- Niche Inheritance: A Cooperative Pathway to Enhance Cancer Cell Fitness Though Ecosystem Engineering.
- A multi-targeted approach to treating bone metastases.
- The Cancer Diaspora: Metastasis beyond the Seed and Soil Hypothesis.
- Beyond the androgen receptor: New approaches to treating metastatic prostate Cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.
- Activating ESR1 mutations in hormone-resistant metastatic breast Cancer.
- A method to measure cellular adhesion utilizing a polymer micro-cantilever.
- TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition.
- The long noncoding RNA SChLAP1 promotes aggressive prostate Cancer and antagonizes the SWI/SNF complex.
- The 19th annual prostate Cancer foundation scientific retreat.
- Erythropoietin supports the survival of prostate Cancer, but not growth and bone metastasis.
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
- Cancer stem cells and their role in metastasis.
- Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.
- Definition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation.
- Circulating fibroblast-like cells in men with metastatic prostate Cancer.
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate Cancer.
- Prostate Cancer and parasitism of the bone hematopoietic stem cell niche.
- The mutational landscape of lethal castration-resistant prostate Cancer.
- Cyclophosphamide creates a receptive microenvironment for prostate Cancer skeletal metastasis.
- Prevalence of prostate Cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.
- Forging the Association for Clinical and Translational Science (ACTS).
- Disrupting the networks of Cancer.
- Role of dutasteride in pre-clinical ETS fusion-positive prostate Cancer models.
- Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and Progenitor Cells To Regulate Bone Phenotype.
- Chemical transfection of dye-conjugated microRNA precursors for microRNA functional analysis of M2 macrophages.
- IL-4 induces proliferation in prostate Cancer PC3???cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin upregulation.
- Common Structural and Epigenetic Changes in the Genome of Castration Resistant Prostate Cancer.
- 384 hanging drop arrays give excellent z-factors and allow versatile formation of co-culture spheroids.
- Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate Cancer patients: a randomized phase II trial by the prostate Cancer clini...
- Personalized oncology through integrative high-throughput sequencing: a pilot study.
- Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates.
- Modeling invasion of metastasizing Cancer cells to bone marrow utilizing ecological principles.
- The importance of proposed changes in the "common rule" for -clinical and translational researchers.
- Centralized Research Recruitment-Evolving a Local Clinical Research Recruitment Web Application to Better Meet User Needs.
- Homing of Cancer Cells to the Bone.
- The Clinical and Translational Science Awards (CTSAs) Are Transforming the Way Academic Medical Institutions Approach Translational Research: The University of Michiga...
- Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors.
- Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
- Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate Cancer.
- Characterization of bone metastases from rapid autopsies of prostate Cancer patients.
- Human prostate Cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.
- Inherited variants in the chemokine CCL2 gene and prostate Cancer aggressiveness in a Caucasian cohort.
- Therapeutic targeting of SPINK1-positive prostate Cancer.
- Nanoparticle induced cell magneto-rotation: monitoring morphology, stress and drug sensitivity of a suspended single Cancer cell.
- Inhibitory effects of megakaryocytic cells in prostate Cancer skeletal metastasis.
- Copy number and targeted mutational analysis reveals novel somatic events in metastatic Prostate tumors.
- Successfully accelerating translational research at an academic medical center: the University of Michigan-Coulter translational research partnership program.
- Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate Cancer patients: a randomized phase II trial by the prostate ...
- AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate Cancer model.
- Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate Cancer growth.
- Single cell trapping in larger microwells capable of supporting cell spreading and proliferation.
- Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate Cancer progression.
- The CTSA mandate: are we there yet?
- Erythropoietin couples hematopoiesis with bone formation.
- CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.
- Alpha 1,3 fucosyltransferases are master regulators of prostate Cancer cell trafficking.
- Treatment-dependent androgen receptor mutations in prostate Cancer exploit multiple mechanisms to evade therapy.
- Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone Cancer model.
- Critical appraisal of prostate-specific antigen in prostate Cancer screening: 20 years later.
- Regulation of prostate Cancer progression by galectin-3.
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate Cancer: a reanalysis of IMMC38 trial data.
- Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and...
- Prostate Cancer promotes CD11b positive cells to differentiate into osteoclasts.
- A destructive cascade mediated by CCL2 facilitates prostate Cancer growth in bone.
- Ecological therapy for Cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel Cancer treatments.
- Tumor expressed PTHrP facilitates prostate Cancer-induced osteoblastic lesions.
- Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate Cancer.
- CCL2, survivin and autophagy: new links with implications in human Cancer.
- Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate Cancer.
- Dickkopf-1 expression increases early in prostate Cancer development and decreases during progression from primary tumor to metastasis.
- CCL2 protects prostate Cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.
- Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate Cancer cells is regulated by TNF-alpha.
- CCL2 induces prostate Cancer transendothelial cell migration via activation of the small GTPase Rac.
- Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate Cancer.
- The current state of preclinical prostate Cancer animal models.
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.
- The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate Cancer.
- Randomized clinical trial of a family intervention for prostate Cancer patients and their spouses.
- A polycomb repression signature in metastatic prostate Cancer predicts Cancer outcome.
- Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate Cancer therapy.
- Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate Cancer tumor regression in vivo.
- Living with prostate Cancer: patients' and spouses' psychosocial status and quality of life.
- The evolving biology and treatment of prostate Cancer.
- Integrative analysis of genomic aberrations associated with prostate Cancer progression.
- A hierarchical network of transcription factors governs androgen receptor-dependent prostate Cancer growth.
- PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
- The lethal phenotype of Cancer: the molecular basis of death due to malignancy.
Schools
Johns Hopkins University School of Medicine
Conditions Treated
- Anemia
- Bladder Cancer
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
Johns Hopkins University -
University of Chicago -
Johns Hopkins University School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1649356510 | |
| NPPES Provider LastName | PIENTA | |
| NPPES Provider FirstName | KENNETH | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 111.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649356510 |
| Last Name Of The Provider | PIENTA |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
|
Dr. Carole B. Miller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohamad E. Allaf, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Stuart A. Grossman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting Bao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. Klebanoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Kanakry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jenny Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Humphrey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas D. Ross, MD
This Doctor is OpenDoctor Recommended.
|